The Relation of Serum Pentraxin-3 Levels with Coronary Artery Ectasia

Year 2013, Volume: 16 Issue: 2, 87 - 92, 01.02.2012

Mustafa Kurt Mehmet Fatih Karakaş Eyup Büyükkaya Şule Büyükkaya Esra Karakaş Sedat Motor Adnan Burak Akçay Nihat Şen Fatih Yalçın

https://doi.org/10.5505/pajes.2012.09719

Abstract

Introduction: Coronary artery ectasia is characterized as the dilation of a segment of coronary artery at least 1.5 times the adjacent segment in which infl ammation, neurohormonal activity and atherosclerosis are held responsible for the pathogenesis. The association between the coronary artery ectasia and infl ammatory markers has been shown, however there is nodata related to Pentraxine 3 (PTX-3). In this study, we investigated the association between serum PTX-3 and high sensitive C-reactive protein (hs-CRP) levels in patients with coronary artery ectasia. Patients and Methods: The study population consisted of 66 patients who underwent coronary angiography with the suspicion of coronary artery disease and 32 controls. Patients were divided in two groups as the coronary artery ectasia group (n= 34) and coronary artery disease group (n= 32). PTX-3 and hs-CRP levels were measured. Results: Serum PTX-3 levels were comparable between coronary artery disease and coronary artery ectasia groups (0.67 ± 0.29 vs. 0.66 ± 0.34, p= 0.63), coronary artery disease and coronary artery ectasia groups had signifi cantly increased PTX-3 levels when compared to the control group (0.67 ± 0.29 vs. 0.32 ± 0.24, p< 0.001; 0.66 ± 0.34 vs. 0.32 ± 0.24, p< 0.001; respectively). Similarly, hs-CRP levels were comparable in coronary artery disease and coronary artery ectasia groups (1.4 ± 0.7 vs. 1.2 ± 0.5, p= 0.19), coronary artrey disease and coronary artery ectasia groups had signifi cantly increased hs-CRP levels when compared to the control group (1.4 ± 0.7 vs. 0.8 ± 0.5, p< 0.001; 1.2 ± 0.5 vs. 0.8 ± 0.5, p< 0.001 respectively). The correlation analysis revealed that serum PTX-3 was associated with hs-CRP (Rho= 0.24, p= 0.016). Conclusion: PTX-3, a novel infl ammatory marker, is elevated in patients with coronary artery ectasia and may be promising biomarker in refl ecting the infl ammatory status in patients with coronary artery ectasia.

Keywords

PTX3 protein; coronary vessels; dilatation, pathologic; infl ammation.

Koroner Arter Ektazisinde Serum Pentraksin-3 Seviyelerinin İncelenmesi

Abstract

Giriş: Koroner arter ektazisi, koroner arterlerin tamamının veya bir bölümünün arterin normal kısmındaki çapına göre 1.5 kat veya daha fazla olmasıyla karakterize durum olup patofi zyolojisinde infl amasyon, nörohormonal aktivite ve ateroskleroz sorumlu tutulmaktadır. Koroner arter ektazisiyle infl amatuvar belirteçlerin ilişkisini gösteren çalışmalar mevcuttur, ancak koroner arter ektazisinin yeni tanımlanan bir infl amatuvar belirteç olan pentraksin-3 (PTX-3) ile ilişkisi konusunda yeterli veri yoktur. Bu çalışmamızda koroner arter ektazisi hastalarında serum PTX-3 ve yüksek duyarlı (high sensitive) C-reaktif protein (hs-CRP) seviyeleri arasındaki ilişkiyi incelemeyi amaçladık. Hastalar ve Yöntem: Bu çalışmaya anjinal semptomları ve pozitif iskemi bulguları olduğu için koroner anjiyografi yapılan 66 hasta ve 32 kontrol hastası dahil edilmiştir. Hastalar koroner arter hastalığı grubu (n= 32) ve koroner arter ektazisi grubuna ayrılmıştır (n= 34). Serum PTX-3 ve hs-CRP seviyeleri ölçülmüştür. Bulgular: Koroner arter ektazisi ve koroner arter hastalığı grubunda kontrol grubuna göre hs-CRP seviyesi yüksekti (koroner arter hastalığı ve kontrol hastası grubu için, 1.4 ± 0.7 vs. 0.8 ± 0.5, p< 0.001; koroner arter ektazisi ve kontrol hastası grubu için, 1.2 ± 0.5 vs. 0.8 ± 0.5, p< 0.001). Koroner arter hastalığı ve koroner arter ektazisi grubunda PTX-3 seviyeleri arasında (0.67 ± 0.29 vs. 0.66 ± 0.34, p= 0.63) belirgin fark olmamasına karşın koroner arter hastalığı (0.67 ± 0.29 vs. 0.32 ± 0.24, p < 0.001) ve koroner arter ektazisi (0.66 ± 0.34 vs. 0.32 ± 0.24, p< 0.001) grubundaki hastaların PTX-3 seviyesi kontrol grubuna göre daha yüksekti. Korelasyon analizi sonucu serum PTX-3 ve hs-CRP seviyeleri birbirleriyle ilişkili bulundu (Rho= 0.24, p= 0.016).Sonuç: Koroner arter ektazisi olan hastalarda yeni bir infl amatuvar belirteç olan PTX-3 yüksek bulunmuştur. Bu durum infl amasyonun koroner arter ektazisi patofi zyolojisinde önemli bir role sahip olduğunu düşündürmektedir.

Keywords

PTX3 protein; koroner damarlar; dilatasyon, patolojik; infl amasyon.

References

• Swaye PS, Fisher LD, Litwin P, Vignola PA, Judkins MP, Kemp HG, et al. Aneurysmal coronary artery disease. Circulation 1983;67:134-8.
• Markis JE, Joffe CD, Cohn PF, Feen DJ, Herman MV, Gorlin R. Clinical signifi cance of coronary arterial ectasia. Am J Cardiol 1976;37:217-22.
• Li JJ, Nie SP, Qian XW, Zeng HS, Zhang CY. Chronic infl am- matory status in patients with coronary artery ectasia. Cytokine 2009;46:61-4.
• Swanton RH, Thomas ML, Coltart DJ, Jenkins BS, Webb-Peploe MM, Williams BT. Coronary artery ectasia--a variant of occlusive coronary arteriosclerosis. British Heart Journal 1978;40:393-400.
• Libby P, Ridker PM, Hansson GK. Infl ammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129- 38.
• Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M et al. Cardioprotective function of the long pentraxin PTX-3 in acute myocardial infarction. Circulation 2008;117:1055-64.
• Befeler B, Aranda MJ, Embi A, Mullin FL, El-Sherif N, Lazzara R. Coronary artery aneurysms: study of the etiology, clinical course and effect on left ventricular function and prognosis. Am J Med 1977;62:597-607.
• Falsetti HL, Carrol RJ. Coronary artery aneurysm. A review of the literature with a report of 11 new cases. Chest 1976;69:630-6.
• Finkelstein A, Michowitz Y, Abashidze A, Miller H, Keren G, Ge- orge J. Temporal association between circulating proteolytic, inf- lammatory and neurohormonal markers in patients with coronary ectasia. Atherosclerosis 2005;179:353-9.
• Demopoulos VP, Olympios CD, Fakiolas CN, Pissimissis EG, Eco- nomides NM, Adamopoulou E, et al. The natural history of aneury- smal coronary artery disease. Heart 1997;78:136-41.
• Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: the concept of “dilated” versus “obstructive” coronary atherosclerosis. J Am Coll Cardiol 2001;38:297-306.
• Bond MG, Adams MR, Bullock BC. Complicating factors in evalu- ating coronary artery atherosclerosis. Artery 1981;9:21-9.
• Pinar Bermudez E, Lopez Palop R, Lozano Martinez-Luengas I, Cortes Sanchez R, Carrillo Saez P, Rodriguez Carreras R, et al.Coronary ectasia: prevalence, and clinical and angiographic characteristics. Revista Espanola de Cardiologia 2003;56:473-9.
• Kruger D, Stierle U, Herrmann G, Simon R, Sheikhzadeh A. Exer- cise-induced myocardial ischemia in isolated coronary artery ec- tasias and aneurysms (dilated coronopathy). J Am Coll Cardiol 1999;34:1461-70.
• Harikrishnan S, Sunder KR, Tharakan J, Titus T, Bhat A, Siva- sankaran S, et al. Coronary artery ectasia: angiographic, clinical profi le and follow-up. Indian Heart Journal 2000;52:547-53.
• Isik T, Kurt M, Ayhan E, Uyarel H, Tanboga IH, Korkmaz AF, et al. Relation of red cell distribution width with presence and severity of coronary artery ectasia. Clinical and applied thrombosis/hemos- tasis: offi cial journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012;18:441-7.
• Turhan H, Erbay AR, Yasar AS, Balci M, Bicer A, Yetkin E. Com- parison of C-reactive protein levels in patients with coronary artery ectasia versus patients with obstructive coronary artery disease. Am J Cardiol 2004;94:1303-6.
• Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010;28:157-83.
• Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al.The long pentraxin PTX-3 in vascular pathology. Vascul Pharmacol 2006;45:326-30.
• Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bot- tazzi B, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 2011;187:970-9.